SK282354B6 - Použitie rekombinantného adenovírusu zvieracieho pôvodu na prípravu farmaceutickej kompozície, rekombinantný adenovírus zvieracieho pôvodu a farmaceutická kompozícia obsahujúca tento adenovírus - Google Patents
Použitie rekombinantného adenovírusu zvieracieho pôvodu na prípravu farmaceutickej kompozície, rekombinantný adenovírus zvieracieho pôvodu a farmaceutická kompozícia obsahujúca tento adenovírus Download PDFInfo
- Publication number
- SK282354B6 SK282354B6 SK1447-95A SK144795A SK282354B6 SK 282354 B6 SK282354 B6 SK 282354B6 SK 144795 A SK144795 A SK 144795A SK 282354 B6 SK282354 B6 SK 282354B6
- Authority
- SK
- Slovakia
- Prior art keywords
- adenovirus
- adenoviruses
- human
- therapeutic
- gene
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 105
- 241001465754 Metazoa Species 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 13
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 26
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 21
- 238000001356 surgical procedure Methods 0.000 claims abstract description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 51
- 102100038909 Caveolin-2 Human genes 0.000 claims description 27
- 101000740981 Homo sapiens Caveolin-2 Proteins 0.000 claims description 27
- 210000005260 human cell Anatomy 0.000 claims description 15
- 241000282465 Canis Species 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 13
- 241000701157 Canine mastadenovirus A Species 0.000 claims description 12
- 241000598171 Human adenovirus sp. Species 0.000 claims description 8
- 230000010076 replication Effects 0.000 claims description 8
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 6
- 230000000692 anti-sense effect Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- -1 trophic factors Proteins 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- 241000701168 Murine adenovirus 1 Species 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 241001503524 Ovine adenovirus Species 0.000 claims description 3
- 241000188845 Porcine adenovirus Species 0.000 claims description 3
- 241000701792 avian adenovirus Species 0.000 claims description 3
- 241000990167 unclassified Simian adenoviruses Species 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 102000007592 Apolipoproteins Human genes 0.000 claims description 2
- 108010071619 Apolipoproteins Proteins 0.000 claims description 2
- 102000008072 Lymphokines Human genes 0.000 claims description 2
- 108010074338 Lymphokines Proteins 0.000 claims description 2
- 239000003914 blood derivative Substances 0.000 claims description 2
- 230000015271 coagulation Effects 0.000 claims description 2
- 238000005345 coagulation Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000002858 neurotransmitter agent Substances 0.000 claims description 2
- 239000002243 precursor Substances 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 230000001228 trophic effect Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 abstract description 24
- 238000001415 gene therapy Methods 0.000 abstract description 9
- 210000004027 cell Anatomy 0.000 description 68
- 239000013612 plasmid Substances 0.000 description 23
- 108020004414 DNA Proteins 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 239000012634 fragment Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000013598 vector Substances 0.000 description 9
- 238000010276 construction Methods 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 108020005202 Viral DNA Proteins 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 230000006798 recombination Effects 0.000 description 6
- 238000005215 recombination Methods 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100021244 Integral membrane protein GPR180 Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 241001135569 Human adenovirus 5 Species 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 108010024878 Adenovirus E1A Proteins Proteins 0.000 description 2
- 108010087905 Adenovirus E1B Proteins Proteins 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 101150005585 E3 gene Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701533 Escherichia virus T4 Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101150047856 Cav2 gene Proteins 0.000 description 1
- 102100035888 Caveolin-1 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 1
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 101150066038 E4 gene Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000004038 Glia Maturation Factor Human genes 0.000 description 1
- 108090000495 Glia Maturation Factor Proteins 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 101000715467 Homo sapiens Caveolin-1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000015336 Nerve Growth Factor Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000035028 Nucleic proteins Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 101100379247 Salmo trutta apoa1 gene Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 101150115889 al gene Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305954A FR2705361B1 (fr) | 1993-05-18 | 1993-05-18 | Vecteurs viraux et utilisation en thérapie génique. |
| PCT/FR1994/000531 WO1994026914A1 (fr) | 1993-05-18 | 1994-05-06 | Vecteurs adenoviraux d'origine animale et utilisation en therapie genique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK144795A3 SK144795A3 (en) | 1996-04-03 |
| SK282354B6 true SK282354B6 (sk) | 2002-01-07 |
Family
ID=9447235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1447-95A SK282354B6 (sk) | 1993-05-18 | 1994-05-06 | Použitie rekombinantného adenovírusu zvieracieho pôvodu na prípravu farmaceutickej kompozície, rekombinantný adenovírus zvieracieho pôvodu a farmaceutická kompozícia obsahujúca tento adenovírus |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6294377B1 (zh) |
| EP (1) | EP0698108B2 (zh) |
| JP (2) | JP3995259B2 (zh) |
| KR (1) | KR100379569B1 (zh) |
| CN (1) | CN1067722C (zh) |
| AT (1) | ATE209686T1 (zh) |
| AU (1) | AU696495B2 (zh) |
| BR (1) | BR9406720A (zh) |
| CA (1) | CA2163256C (zh) |
| CZ (1) | CZ284903B6 (zh) |
| DE (1) | DE69429260T3 (zh) |
| DK (1) | DK0698108T4 (zh) |
| ES (1) | ES2167365T5 (zh) |
| FI (1) | FI118538B (zh) |
| FR (1) | FR2705361B1 (zh) |
| HU (1) | HU221340B1 (zh) |
| IL (1) | IL109644A (zh) |
| NO (1) | NO320818B1 (zh) |
| NZ (1) | NZ266475A (zh) |
| PL (1) | PL182814B1 (zh) |
| PT (1) | PT698108E (zh) |
| RU (1) | RU2233333C2 (zh) |
| SK (1) | SK282354B6 (zh) |
| UA (1) | UA66417C2 (zh) |
| WO (1) | WO1994026914A1 (zh) |
| ZA (1) | ZA943358B (zh) |
Families Citing this family (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
| CA2108144A1 (en) | 1991-03-06 | 1992-09-07 | Jack A. Roth | Methods and compositions for the selective inhibition of gene expression |
| US5747469A (en) | 1991-03-06 | 1998-05-05 | Board Of Regents, The University Of Texas System | Methods and compositions comprising DNA damaging agents and p53 |
| IL113052A0 (en) | 1994-03-23 | 1995-06-29 | Rhone Poulenc Rorer Sa | Recombinant viruses, their preparation and their use in gene therapy |
| WO1995034671A1 (en) | 1994-06-10 | 1995-12-21 | Genvec, Inc. | Complementary adenoviral vector systems and cell lines |
| FR2722507B1 (fr) * | 1994-07-12 | 1996-08-14 | Rhone Poulenc Rorer Sa | Adenovirus comportant un gene codant pour une no synthase |
| FR2724320B1 (fr) * | 1994-09-13 | 1996-12-20 | Transgene Sa | Nouvel implant pour le traitement des maladies acquises |
| FR2725213B1 (fr) * | 1994-10-04 | 1996-11-08 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation en therapie genique |
| FR2726285B1 (fr) | 1994-10-28 | 1996-11-29 | Centre Nat Rech Scient | Adenovirus depourvus de particules contaminantes viables, preparation et utilisation |
| FR2727689A1 (fr) | 1994-12-01 | 1996-06-07 | Transgene Sa | Nouveau procede de preparation d'un vecteur viral |
| CN100569297C (zh) | 1995-02-28 | 2009-12-16 | 加利福尼亚大学董事会 | 基因转移介导的血管形成疗法 |
| US6752987B1 (en) | 1995-02-28 | 2004-06-22 | The Regents Of The University Of California | Adenovirus encoding human adenylylcyclase (AC) VI |
| FR2731710B1 (fr) * | 1995-03-14 | 1997-04-30 | Rhone Poulenc Rorer Sa | Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique |
| FR2732357B1 (fr) * | 1995-03-31 | 1997-04-30 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose |
| US6281010B1 (en) | 1995-06-05 | 2001-08-28 | The Trustees Of The University Of Pennsylvania | Adenovirus gene therapy vehicle and cell line |
| US5698202A (en) * | 1995-06-05 | 1997-12-16 | The Wistar Institute Of Anatomy & Biology | Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier |
| US6019978A (en) * | 1995-06-05 | 2000-02-01 | The Wistar Institute Of Anatomy And Biology | Replication-defective adenovirus human type 5 recombinant as a vaccine carrier |
| US5756283A (en) * | 1995-06-05 | 1998-05-26 | The Trustees Of The University Of Pennsylvania | Method for improved production of recombinant adeno-associated viruses for gene therapy |
| DK0833934T4 (da) | 1995-06-15 | 2012-11-19 | Crucell Holland Bv | Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi |
| US6265212B1 (en) | 1995-06-15 | 2001-07-24 | Introgene B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| AUPN477695A0 (en) * | 1995-08-14 | 1995-09-07 | Commonwealth Scientific And Industrial Research Organisation | Gene therapy |
| FR2740344B1 (fr) * | 1995-10-31 | 1997-11-21 | Rhone Poulenc Rorer Sa | Application de la proteine gax au traitement de cancers |
| EP0979101B1 (en) * | 1996-07-03 | 2010-10-27 | Merial, Inc. | Recombinant canine adenovirus 2 (cav2) containing exogenous dna |
| AU4255397A (en) * | 1996-09-06 | 1998-03-26 | Trustees Of The University Of Pennsylvania, The | Chimpanzee adenovirus vectors |
| JP2001523103A (ja) | 1997-04-28 | 2001-11-20 | ローヌ−プーラン・ロレ・エス・アー | 腫瘍治療用血管形成アンタゴニストのアデノウイルスによる腫瘍内送達 |
| JP2002516061A (ja) | 1997-10-14 | 2002-06-04 | ダーウィン モレキュラー コーポレイション | チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質 |
| US6875606B1 (en) | 1997-10-23 | 2005-04-05 | The United States Of America As Represented By The Department Of Veterans Affairs | Human α-7 nicotinic receptor promoter |
| US6653088B1 (en) | 1997-10-24 | 2003-11-25 | Aventis Pharma S.A. | Interaction test for the investigation of inhibitory molecules of the interaction between a presenilin and the β-amyloid peptide |
| DK1049767T3 (da) | 1998-01-08 | 2005-09-19 | Aventis Pharma Inc | En transgen kanin, der udtrykker et funktionelt humant lipoprotein(A) |
| US6670188B1 (en) | 1998-04-24 | 2003-12-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6225456B1 (en) | 1998-05-07 | 2001-05-01 | University Technololy Corporation | Ras suppressor SUR-5 |
| US6506889B1 (en) | 1998-05-19 | 2003-01-14 | University Technology Corporation | Ras suppressor SUR-8 and related compositions and methods |
| DE69943129D1 (de) | 1998-08-11 | 2011-02-24 | Darwin Discovery Ltd | Identifikation des gens das zum schorfigen phenotyp der maus führt, sowie seines menschlichen orthologs |
| BRPI9915679B8 (pt) | 1998-11-27 | 2021-05-25 | Darwin Discovery Ltd | composições e métodos para aumentar a mineralização óssea |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| US7063850B1 (en) | 1998-12-22 | 2006-06-20 | University Of Tennessee Research Foundation | Protective antigen of group A Streptococci |
| US6441156B1 (en) * | 1998-12-30 | 2002-08-27 | The United States Of America As Represented By The Department Of Health And Human Services | Calcium channel compositions and methods of use thereof |
| FR2794771B1 (fr) * | 1999-06-11 | 2001-08-10 | Aventis Pharma Sa | Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis) |
| FR2799472B1 (fr) | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
| CA2395839A1 (en) * | 1999-12-27 | 2001-07-05 | The Regents Of The University Of California | Gene therapy for congestive heart failure |
| EP2163561A1 (en) | 2000-01-12 | 2010-03-17 | Yale University | NOGO receptor-mediated blockade of axonal growth |
| ES2551164T3 (es) | 2000-03-24 | 2015-11-16 | Biosphere Medical, Inc. | Microesferas para embolización activa |
| GB0018307D0 (en) | 2000-07-26 | 2000-09-13 | Aventis Pharm Prod Inc | Polypeptides |
| US7060442B2 (en) | 2000-10-30 | 2006-06-13 | Regents Of The University Of Michigan | Modulators on Nod2 signaling |
| DE60144198D1 (de) | 2000-12-28 | 2011-04-21 | Wyeth Llc | Rekombinantes schutzprotein aus streptococcus pneumoniae |
| US7507542B2 (en) | 2001-05-08 | 2009-03-24 | Ucb Sa | Method for regulating immune function using the FOXP3 protein |
| AUPR518501A0 (en) | 2001-05-22 | 2001-06-14 | Unisearch Limited | Yin yang-1 |
| WO2003004088A2 (en) | 2001-07-05 | 2003-01-16 | Aventis Pharma S.A. | Method of administration of a gene of interest to the heart and vasculature |
| US7108975B2 (en) | 2001-09-21 | 2006-09-19 | Regents Of The University Of Michigan | Atlastin |
| US7582425B2 (en) | 2001-09-21 | 2009-09-01 | The Regents Of The University Of Michigan | Atlastin |
| US20040023910A1 (en) * | 2001-09-28 | 2004-02-05 | Zhiming Zhang | Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas |
| MX339524B (es) | 2001-10-11 | 2016-05-30 | Wyeth Corp | Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica. |
| AU2002365223A1 (en) | 2001-10-26 | 2003-09-02 | Id Biomedical Corporation Of Washington | Multivalent streptococcal vaccine compositions and methods for use |
| WO2003049763A1 (en) | 2001-12-12 | 2003-06-19 | Fh Faulding & Co Limited | Composition for the preservation of viruses |
| US20030158112A1 (en) | 2002-02-15 | 2003-08-21 | Johns Hopkins University School Of Medicine | Selective induction of apoptosis to treat ocular disease |
| EP2316922B1 (en) | 2002-05-24 | 2013-05-22 | Merck Sharp & Dohme Corp. | Neutralizing human anti-IGFR antibody |
| US7785608B2 (en) | 2002-08-30 | 2010-08-31 | Wyeth Holdings Corporation | Immunogenic compositions for the prevention and treatment of meningococcal disease |
| FR2845395B1 (fr) * | 2002-10-08 | 2008-05-30 | Agronomique Inst Nat Rech | Vecteurs adenoviraux recombinants et leurs applications |
| US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
| US7432057B2 (en) | 2004-01-30 | 2008-10-07 | Michigan State University | Genetic test for PSE-susceptible turkeys |
| BR122013008865B8 (pt) | 2004-05-26 | 2021-05-25 | Psioxus Therapeutics Ltd | adenovírus oncolítico de replicação competente |
| US7604798B2 (en) | 2004-07-15 | 2009-10-20 | Northwestern University | Methods and compositions for importing nucleic acids into cell nuclei |
| AU2005274948B2 (en) | 2004-07-16 | 2011-09-22 | Genvec, Inc. | Vaccines against aids comprising CMV/R-nucleic acid constructs |
| US10000757B2 (en) | 2005-05-27 | 2018-06-19 | Ospedale San Raffaele S.R.L. | Gene vector |
| AU2007217366A1 (en) | 2006-02-27 | 2007-08-30 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
| JP2009544731A (ja) | 2006-07-28 | 2009-12-17 | サノフィ−アベンティス | 腫瘍治療のための組成物及び方法 |
| CN101588816B (zh) | 2006-10-19 | 2013-06-19 | Csl有限公司 | 白介素-13受体α1的高亲和性抗体拮抗物 |
| ES2388567T3 (es) | 2006-10-19 | 2012-10-16 | Csl Limited | Anticuerpos anti-il-13r alfa 1 y usos de los mismos |
| AR064642A1 (es) | 2006-12-22 | 2009-04-15 | Wyeth Corp | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi |
| US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
| JP2012508174A (ja) | 2008-11-05 | 2012-04-05 | ワイス・エルエルシー | β溶血性連鎖球菌（ＢＨＳ）疾患を予防するための多成分免疫原性組成物 |
| US20110293608A1 (en) | 2008-12-03 | 2011-12-01 | The Johns Hopkins Univeristy | Annexin a2 as immunological target |
| MX2011005910A (es) * | 2008-12-04 | 2011-06-17 | Opko Curna Llc | Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina. |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| AU2011227050B2 (en) | 2010-03-19 | 2016-12-08 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| CN102947451B (zh) * | 2010-05-26 | 2017-09-22 | 库尔纳公司 | 通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病 |
| US9771579B2 (en) * | 2010-06-23 | 2017-09-26 | Curna, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA |
| AU2011294776B2 (en) | 2010-08-23 | 2016-02-04 | Wyeth Llc | Stable formulations of Neisseria meningitidis rLP2086 antigens |
| CA2809758C (en) | 2010-09-10 | 2021-07-13 | Wyeth Llc | Non-lipidated variants of neisseria meningitidis orf2086 antigens |
| WO2012135696A2 (en) | 2011-04-01 | 2012-10-04 | University Of South Alabama | Methods and compositions for the diagnosis, classification, and treatment of cancer |
| WO2013103401A1 (en) | 2012-01-06 | 2013-07-11 | University Of South Alabama | Methods and compositions for the treatment of cancer |
| SA115360586B1 (ar) | 2012-03-09 | 2017-04-12 | فايزر انك | تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها |
| EP4043029A1 (en) | 2012-03-09 | 2022-08-17 | Pfizer Inc. | Neisseria meningitidis compositions and methods thereof |
| WO2013169399A1 (en) | 2012-05-07 | 2013-11-14 | The Regents Of The University Of California | Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
| WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
| CN105189755A (zh) * | 2013-01-15 | 2015-12-23 | 加利福尼亚大学董事会 | 腺病毒及其用途 |
| ES2685894T3 (es) | 2013-03-08 | 2018-10-15 | Pfizer Inc. | Polipéptidos de fusión inmunogénicos |
| WO2014164703A1 (en) | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Inc. | Delivery of card protein as therapy for occular inflammation |
| US9683009B2 (en) | 2013-05-02 | 2017-06-20 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
| MX369534B (es) | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
| PL3021859T3 (pl) | 2013-10-25 | 2018-06-29 | Psioxus Therapeutics Limited | Adenowirusy onkolityczne wyposażone w geny heterolityczne |
| WO2015127094A1 (en) | 2014-02-19 | 2015-08-27 | University Of Florida Research Foundation, Inc. | Delivery of nrf2 as therapy for protection against reactive oxygen species |
| ES2765463T3 (es) | 2014-06-17 | 2020-06-09 | Nippon Shinyaku Co Ltd | Acido nucleico antisentido para usar en el tratamiento de la distrofia muscular de Duchenne |
| EP3250279B1 (en) | 2015-01-30 | 2020-08-19 | The Regents of the University of California | Spinal subpial gene delivery system |
| RU2723045C2 (ru) | 2015-02-19 | 2020-06-08 | Пфайзер Инк. | Композиции neisseria meningitidis и способы их получения |
| MX2017013684A (es) | 2015-04-30 | 2018-08-28 | Psioxus Therapeutics Ltd | Adenovirus oncolitico que codifica una proteina b7. |
| CN108289909A (zh) | 2015-10-19 | 2018-07-17 | 巴尔的摩马里兰大学 | 用于产生工程改造的人原代血液树突细胞系的方法 |
| CA3006859A1 (en) | 2015-12-17 | 2017-06-22 | Psioxus Therapeutics Limited | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| US11472859B2 (en) | 2016-03-28 | 2022-10-18 | The Regents Of The University Of California | Method and composition for treating neuronal hyper-excitabtiity |
| US11560412B2 (en) | 2016-04-01 | 2023-01-24 | University Of Maryland, Baltimore | Compositions comprising GRIM-19 therapeutics and methods of use |
| KR20240096679A (ko) | 2016-04-20 | 2024-06-26 | 센트로 데 인베스띠가씨오네스 에너제티까스 메디오암비엔딸레스 와이 테크놀로지까스, 오.에이., 엠.피. | Pklr의 유전자 발현 증강을 위한 조성물 및 방법 |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CN109862912B (zh) | 2016-08-29 | 2024-08-02 | 阿卡米斯生物公司 | 携带双特异性t细胞衔接器的腺病毒 |
| WO2018057441A1 (en) | 2016-09-20 | 2018-03-29 | Boehringer Ingelheim Vetmedica Gmbh | Canine adenovirus vectors |
| KR102618843B1 (ko) | 2016-09-20 | 2024-01-02 | 베링거잉겔하임베트메디카게엠베하 | 신규한 ehv 삽입 부위 orf70 |
| KR102566066B1 (ko) | 2016-09-20 | 2023-08-16 | 베링거잉겔하임베트메디카게엠베하 | 신규한 돼지 인플루엔자 백신 |
| BR112019005418A2 (pt) | 2016-09-20 | 2019-10-01 | Boehringer Ingelheim Vetmedica Gmbh | novos promotores |
| MX2019009011A (es) | 2017-01-31 | 2019-09-26 | Pfizer | Composiciones de neisseria meningitidis y metodos respectivos. |
| BR112020007444A2 (pt) | 2017-10-16 | 2020-10-20 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | vetores lentivirais para a liberação de pklr para tratar deficiência de piruvato quinase |
| US20200237799A1 (en) | 2017-10-16 | 2020-07-30 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
| TWI804518B (zh) | 2017-10-16 | 2023-06-11 | 美商航海家醫療公司 | 肌萎縮性脊髓側索硬化症(als)之治療 |
| EP3973973A1 (en) | 2017-10-31 | 2022-03-30 | KaliVir Immunotherapeutics, Inc. | Platform oncolytic vector for systemic delivery |
| US20210361318A1 (en) | 2018-07-02 | 2021-11-25 | Voyager Therapeutics, Inc. | Cannula system and use thereof |
| AU2019299861A1 (en) | 2018-07-02 | 2021-01-14 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
| WO2021247995A2 (en) | 2020-06-04 | 2021-12-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating neuropathic pain |
| IL300263A (en) | 2020-08-07 | 2023-03-01 | Spacecraft Seven Llc | Plakophilin-2 (PKP2) gene therapy using an AAV vector |
| CA3215344A1 (en) | 2021-04-30 | 2022-11-03 | Kalivir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| AU2022371414A1 (en) | 2021-10-20 | 2024-05-02 | University Of Copenhagen | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss |
| US20230270818A1 (en) | 2021-11-02 | 2023-08-31 | University Of Rochester | Tcf7l2 mediated remyelination in the brain |
| WO2024091824A1 (en) | 2022-10-26 | 2024-05-02 | Ada Forsyth Institute, Inc. | Differentiation and reprogramming of chondrocyte |
| WO2024163747A2 (en) | 2023-02-02 | 2024-08-08 | University Of Rochester | Competitive replacement of glial cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA858044B (en) * | 1984-11-01 | 1987-05-27 | American Home Prod | Oral vaccines |
| IE903130A1 (en) * | 1989-09-15 | 1991-03-27 | Regeneron Pharma | Ciliary neurotrophic factor |
| GB9001766D0 (en) * | 1990-01-25 | 1990-03-28 | Univ Court Of The University O | Vaccines |
| FR2681786A1 (fr) * | 1991-09-27 | 1993-04-02 | Centre Nat Rech Scient | Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires. |
| FR2688514A1 (fr) * | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant. |
| AU670933B2 (en) * | 1992-03-27 | 1996-08-08 | Collimore Enterprises Pty Ltd | Formwork device |
-
1993
- 1993-05-18 FR FR9305954A patent/FR2705361B1/fr not_active Expired - Lifetime
-
1994
- 1994-05-06 SK SK1447-95A patent/SK282354B6/sk not_active IP Right Cessation
- 1994-05-06 US US08/553,317 patent/US6294377B1/en not_active Expired - Lifetime
- 1994-05-06 CZ CZ953028A patent/CZ284903B6/cs not_active IP Right Cessation
- 1994-05-06 DK DK94916259T patent/DK0698108T4/da active
- 1994-05-06 PT PT94916259T patent/PT698108E/pt unknown
- 1994-05-06 CN CN94192150A patent/CN1067722C/zh not_active Expired - Lifetime
- 1994-05-06 UA UA95114778A patent/UA66417C2/xx unknown
- 1994-05-06 BR BR9406720A patent/BR9406720A/pt not_active Application Discontinuation
- 1994-05-06 NZ NZ266475A patent/NZ266475A/xx not_active IP Right Cessation
- 1994-05-06 JP JP52504994A patent/JP3995259B2/ja not_active Expired - Lifetime
- 1994-05-06 RU RU95122419/13A patent/RU2233333C2/ru active
- 1994-05-06 DE DE69429260T patent/DE69429260T3/de not_active Expired - Lifetime
- 1994-05-06 HU HU9503297A patent/HU221340B1/hu unknown
- 1994-05-06 ES ES94916259T patent/ES2167365T5/es not_active Expired - Lifetime
- 1994-05-06 AU AU67878/94A patent/AU696495B2/en not_active Expired
- 1994-05-06 PL PL94311660A patent/PL182814B1/pl unknown
- 1994-05-06 CA CA002163256A patent/CA2163256C/fr not_active Expired - Lifetime
- 1994-05-06 AT AT94916259T patent/ATE209686T1/de active
- 1994-05-06 KR KR1019950705128A patent/KR100379569B1/ko not_active IP Right Cessation
- 1994-05-06 WO PCT/FR1994/000531 patent/WO1994026914A1/fr active IP Right Grant
- 1994-05-06 EP EP94916259A patent/EP0698108B2/fr not_active Expired - Lifetime
- 1994-05-12 IL IL10964494A patent/IL109644A/xx not_active IP Right Cessation
- 1994-05-16 ZA ZA943358A patent/ZA943358B/xx unknown
-
1995
- 1995-11-07 NO NO19954466A patent/NO320818B1/no not_active IP Right Cessation
- 1995-11-17 FI FI955552A patent/FI118538B/fi not_active IP Right Cessation
-
2004
- 2004-02-05 JP JP2004029636A patent/JP2004180689A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK282354B6 (sk) | Použitie rekombinantného adenovírusu zvieracieho pôvodu na prípravu farmaceutickej kompozície, rekombinantný adenovírus zvieracieho pôvodu a farmaceutická kompozícia obsahujúca tento adenovírus | |
| RU2219241C2 (ru) | Дефектный рекомбинантный аденовирусный вектор (варианты) | |
| US6669942B2 (en) | Defective adenoviruses including a therapeutic gene and an immunoprotectove gene | |
| KR100403708B1 (ko) | 재조합아데노-수반바이러스(aav)제조방법및이의용도 | |
| ES2264123T3 (es) | Adenovirus recombinantes defectivos para la terapia genica de tumores. | |
| JP4733795B2 (ja) | ヒツジアデノウイルスベクターを用いた遺伝子治療 | |
| JPH11507835A (ja) | 組換えアデノウイルス、ａａｖを作製するためのその使用、相補的細胞系、及び、該アデノウイルスを含む医薬組成物 | |
| KR100796060B1 (ko) | 아데노바이러스 벡터 및 상동 재조합 현상을 줄이는 방법 | |
| AU753809B2 (en) | Recombinant adenoviral vectors comprising a splicing sequence | |
| US20030004091A1 (en) | Medicinal combination useful for in vivo exogenic transfection and expression | |
| AU712304B2 (en) | Deffective recombinant adenoviruses with inactivated IVa2 gene | |
| JP2007530004A (ja) | 疾患を処置するためのサブグループｂアデノウイルスベクター | |
| US7264818B2 (en) | BAV packaging regions and E1 transcriptional control regions | |
| FR2729674A1 (fr) | Cellules pour la production d'adenovirus recombinants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Patent expired |
Expiry date: 20140506 |